Search Results
Your search for ,iII matches 9601 pages
Showing 4201 - 4250NALA Trial: Neratinib/Capecitabine vs Lapatinib/Capecitabine for Pretreated Patients With HER2-Positive Metastatic Breast Cancer
As reported in the Journal of Clinical Oncology by Cristina Saura, MD, and colleagues, the phase III NALA trial has shown significantly prolonged progression-free survival with neratinib/capecitabine vs lapatinib/capecitabine in patients with HER2-positive metastatic breast cancer who had received...
FDA Approves Atezolizumab Plus Cobimetinib/Vemurafenib for Advanced BRAF V600–Mutated Melanoma
On July 30, the U.S. Food and Drug Administration (FDA) approved the PD-L1 inhibitor atezolizumab (Tecentriq) plus the MEK inhibitor cobimetinib (Cotellic) and the selective BRAF kinase inhibitor vemurafenib (Zelboraf) for the treatment of patients with advanced BRAF V600 mutation–positive...
First-Line S-1 Plus Leucovorin and Oxaliplatin vs S-1 Plus Cisplatin in Advanced Gastric Cancer
As reported in The Lancet Oncology by Kang et al, the Japanese-Korean phase III SOLAR trial showed that oral tegafur/gimeracil/oteracil, a combination known as S-1, plus leucovorin and oxaliplatin was associated with a modest but significant improvement in overall survival vs S-1 plus cisplatin in...
Impact of Pregnancy After Breast Cancer in Women With Deleterious Germline BRCA Mutations
In a retrospective cohort study reported in the Journal of Clinical Oncology, Matteo Lambertini, MD, PhD, and colleagues found that pregnancy after breast cancer in women harboring deleterious germline BRCA mutations did not appear to be associated with worsened maternal prognosis or fetal...
Expert Point of View: Michele Teng, PhD
Study discussant Michele Teng, PhD, of QIMR Berghofer Medical Research Institute, Brisbane, Australia, commented: “Cancer immunotherapy is a new pillar of cancer treatment. The aim is to improve the overall survival of patients with cancer, but there is room for improvement, and various...
Anti-TIGIT Antibody Plus Atezolizumab Move Forward in Advanced NSCLC
Tiragolumab, an anti-TIGIT antibody, plus the PD-L1 inhibitor atezolizumab exhibited early clinical activity and was tolerated in patients with advanced solid tumors, including those with metastatic non–small cell lung cancer (NSCLC) that was PD-L1–positive and untreated with prior checkpoint...
CANDOR Trial: Carfilzomib, Dexamethasone, and Daratumumab vs Carfilzomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
As reported in The Lancet by Meletios Dimopoulos, MD, and colleagues, the phase III CANDOR trial has shown prolonged progression-free survival with carfilzomib, dexamethasone, and daratumumab (KdD) vs carfilzomib and dexamethasone (Kd) in patients with relapsed or refractory multiple myeloma....
Expert Point of View: Philip A. Philip, MD, PhD, FRCP
The study’s invited discussant, Philip A. Philip, MD, PhD, FRCP, Professor of Oncology, Pharmacology, and Medicine and the Kathryn Cramer Endowed Chair in Cancer Research at Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, asked whether another triplet regimen was...
First-Line Liposomal Irinotecan–Containing Regimen Studied in Advanced Pancreatic Cancer
In patients with newly diagnosed locally advanced or metastatic pancreatic adenocarcinoma, treatment with liposomal irinotecan plus fluorouracil (5-FU), leucovorin, and oxaliplatin (NALIRIFOX) resulted in a median progression-free survival of 9.2 months and a median overall survival of 12.6 months, ...
Expert Point of View: David Sallman, MD
David Sallman, MD, Assistant Member of the Malignant Hematology Department at Moffitt Cancer Center and Research Institute, Tampa, Florida, commented on these findings for The ASCO Post. “Although the hypomethylating agent azacitidine represents a standard of care for higher-risk myelodysplastic...
Prominent Surgeon and Teacher LaSalle D. Leffall, Jr, MD, Promotes Hard Work and Education to Overcome Boundaries
LaSalle D. Leffall, Jr, MD, the Charles R. Drew Professor of Surgery at Howard University College of Medicine in Washington, DC, died on May 25, 2019, at the age of 89. The ASCO Post paid tribute to Dr. Leffall in its July 10, 2019, issue. Here, as part of our 10-Year Anniversary Series, we...
Role of Rituximab in the Treatment of Children and Adolescents With Mature B-Cell Non-Hodgkin Lymphoma
Minard-Colin et al recently reported for the European Intergroup for Childhood Non-Hodgkin Lymphoma/Children’s Oncology Group (EICNHL/COG) a significant improvement in event-free survival among children and adolescents (aged 6 months to 18 years) with high-risk mature B-cell non-Hodgkin lymphoma...
New Guideline for Locally Advanced Esophageal Cancer Supports Multimodality Therapy and Multidisciplinary Treatment
ASCO has released a new guideline for the treatment of locally advanced esophageal cancer that will provide a context for the current standards of care, fill gaps in clinicians’ knowledge of therapy options, and help define future treatment.1 An expert panel developed the guideline based on 17...
Addition of Rituximab to Standard Chemotherapy Improves Event-Free and Overall Survival in Children With High-Risk, Mature B-Cell Non-Hodgkin Lymphoma
In a European Intergroup for Childhood Non-Hodgkin Lymphoma/Children’s Oncology Group phase III trial reported in The New England Journal of Medicine, Véronique Minard‑Colin, MD, PhD, of Gustave Roussy, Université Paris-Saclay, Villejuif, France, and colleagues found that the addition of rituximab...
Nivolumab in Previously Treated Esophageal Squamous Cell Carcinoma
On June 10, 2020, nivolumab was approved for treatment of patients with unresectable, advanced, recurrent, or metastatic esophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based chemotherapy.1,2 Supporting Efficacy Data Approval was based on findings from the open-label,...
Phase III PADA-1 Trial Examines the Impact of ESR1 Mutations in Metastatic Breast Cancer
ESR1 mutations are known to confer resistance to endocrine therapy in the metastatic breast cancer setting. These mutations herald a poor prognosis, so their clearance early in the treatment course may greatly reduce the risk of recurrence, according to the early results of the prospective phase...
Expert Point of View: Komal Jhaveri, MD
“Surprisingly, the phase II PARSIFAL trial did not show a statistical superiority in progression-free survival for fulvestrant plus palbociclib over letrozole plus palbociclib in the first-line treatment of patients with endocrine-sensitive, metastatic breast cancer. The noninferiority hypothesis...
In Case You Missed It: Quick Takes on Novel Therapies for Solid and Hematologic Malignancies
Because of the COVID-19 pandemic, oncology providers from around the world had to forgo their annual trip to McCormick Place—but the show did go on. We all realized important research can still be presented, clinicians and fellow researchers will still listen, and ASCO presentations will still...
Double PIK3CA Mutations and Response Benefit in Breast Cancer
Patients who have breast cancers with double PIK3CA mutations seem to have a more robust response to PI3Kα inhibitors than those with a single PIK3CA mutation, based on an analysis of the phase III SANDPIPER trial, which tested taselisib plus fulvestrant, according to a presentation during the 2020 ...
Expert Point of View: Ahmad Tarhini, MD, PhD, and Larisa J. Geskin, MD
Ahmad Tarhini, MD, PhD, Director of Cutaneous and Translational Research at Moffitt Cancer Center, Tampa, was optimistic about neoadjuvant use of nivolumab/ipilimumab and looks forward to further randomized studies. “Taken together, the results of the OpACIN and OpACIN-neo trials support the value ...
Small Study Evaluates Neoadjuvant vs Adjuvant Nivolumab Plus Ipilimumab in Stage III Melanoma
The neoadjuvant combination of nivolumab and ipilimumab yielded a continued benefit in relapse-free survival vs adjuvant use of the same combination therapy in 20 patients with stage III macroscopic melanoma. This finding is based on 3-year follow-up results of the phase Ib OpACIN trial, presented...
Monumental Progress in the Treatment of Diffuse Large B-Cell Lymphoma
Some monuments are difficult to topple. At least that was the case dating back to 1976, when investigators from the Southwest Oncology Group demonstrated the importance of doxorubicin in the treatment of patients with a group of lymphoid malignancies then referred to as diffuse aggressive...
Nivolumab/Ipilimumab Shows Benefit in Patients With Non–Small Cell Lung Cancer and Brain Metastases
The combination of nivolumab plus ipilimumab was at least as effective as chemotherapy in front-line therapy for patients with advanced non–small cell lung cancer (NSCLC) and brain metastases at baseline, according to the results of a post hoc analysis from part 1 of the phase III CheckMate 227...
In Keynote Lecture, Anthony Fauci, MD, Explores What We Know About COVID-19 and What’s Being Done to Combat It
Kicking off the American Association for Cancer Research (AACR) Virtual Meeting: COVID-19 and Cancer earlier this week, Anthony Fauci, MD, gave the keynote lecture, “Coronavirus Infections: More Than Just the Common Cold.” As Dr. Fauci told listeners, “[COVID-19]—and other infectious...
Andrew H. Wei, MBBS, PhD, on AML: Venetoclax Plus Cytarabine in Older Patients
Andrew H. Wei, MBBS, PhD, of The Alfred Hospital, Monash University, discusses phase III data from the VIALE-C trial, which appear to support the use of venetoclax plus low-dose cytarabine as a front-line treatment for older patients with acute myeloid leukemia, as well as for those who cannot...
FDA Pipeline: Novel Treatments for Hematologic Malignancies
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to pembrolizumab for the second-line treatment of patients with relapsed or refractory Hodgkin lymphoma, and also accepted a supplemental new drug application for selinexor for pretreated patients with multiple myeloma....
Phase Ib Trial of Atezolizumab With or Without Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma
The combination of atezolizumab and bevacizumab was recently approved by the U.S. Food and Drug Administration for the treatment of unresectable or metastatic hepatocellular carcinoma on the basis of findings from the phase III IMbrave150 trial, which showed superior overall and progression-free...
LACC Trial: Quality of Life With Open vs Minimally Invasive Radical Hysterectomy for Patients With Cervical Cancer
As reported in The Lancet Oncology by Frumovitz et al, there were no significant differences in quality of life, a secondary endpoint, for women undergoing open vs minimally invasive radical hysterectomy for cervical cancer in the phase III LACC trial. There were, however, differences in...
VIALE-A Trial Supports Survival Benefit of Venetoclax Plus Azacitidine in Elderly Patients With AML
In the phase III VIALE-A trial, venetoclax added to azacitidine led to a significant and clinically meaningful improvement in response rates and overall survival, as compared with azacitidine alone, in treatment-naive predominantly elderly patients with acute myeloid leukemia (AML) ineligible for...
Experimental COVID-19 Vaccine Generates Immune Response, Deemed Safe in Phase I Trial
According to a press release from the National Institutes of Health, an investigational vaccine designed to protect against SARS-CoV-2, the virus that causes COVID-19—mRNA-1273—was generally well tolerated and prompted neutralizing antibody activity in healthy adults. These interim results were...
Expert Point of View: Craig Hofmeister, MD, MPH
“The IKEMA trial is based on the interest of adding a CD38 naked antibody to a carfilzomib-plus-dexamethasone skeleton, a protocol nearly identical to the recently presented CANDOR trial,” said Craig Hofmeister MD, MPH, Associate Professor of Hematology and Oncology at the Winship Cancer Institute...
Combination of Isatuximab, Carfilzomib, and Dexamethasone Reduces Risk of Disease Progression in Myeloma
The addition of the CD38 antibody isatuximab-irfc to carfilzomib and dexamethasone nearly halved the risk of disease progression or death in patients with relapsed or refractory multiple myeloma, the interim analysis of the phase III IKEMA trial has shown.1 “Isatuximab plus carfilzomib and...
Presence of ctDNA and CTCs and Prediction of Disease Recurrence in Patients With Triple-Negative Breast Cancer
In a preplanned secondary analysis of the BRE12-158 trial published in JAMA Oncology, Milan Radovich, PhD, and colleagues found that the presence of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) in the plasma of women who have received neoadjuvant treatment for stage I, II, or...
Liver Transplantation After Tumor Downstaging in Patients With Hepatocellular Carcinoma
In an Italian phase IIb/III study reported in The Lancet Oncology, Mazzaferro et al found evidence that liver transplantation after tumor downstaging was associated with improved event-free and overall survival in patients with hepatocellular carcinoma. The study was closed early due to changes in...
Effect of Medicaid Expansion on Breast Cancer Stage at Diagnosis
In a study reported in JAMA Surgery, Le Blanc et al found that Medicaid expansion under the Affordable Care Act was associated with increased insurance coverage and reduction in rates of diagnosis of breast cancer at later stages. Study Details The study involved data from the National Cancer...
Atezolizumab as First-Line Treatment of Metastatic NSCLC With High PD-L1 Expression and No EGFR or ALK Aberrations
On May 18, 2020, atezolizumab was approved for the first-line treatment of adult patients with metastatic non–small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression and no EGFR or ALK genomic tumor aberrations. High PD-L1 expression is defined as PD-L1 staining of at least 50% of...
Do Not Rush to High-Dose Twice-Daily Radiation for Limited Small Cell Lung Cancer
Bjørn Henning Gronberg, MD, PhD, presented a paper at the ASCO20 Virtual Scientific Program reporting astounding positive results favoring higher-dose, twice-daily radiation therapy in limited-stage small cell lung cancer.1 This was a phase II study (large for phase II but small for phase III)...
Atezolizumab Plus Bevacizumab for Unresectable or Metastatic Hepatocellular Carcinoma
On May 29, 2020, atezolizumab in combination with bevacizumab was approved for treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.1-3 Supporting Efficacy Data Approval was based on findings in the international, open-label,...
IMbrave150: A New Standard of Care to Treat Hepatocellular Cancers?
In 2007, sorafenib became the first approved systemic therapy for hepatocellular cancers and the first agent to improve overall survival in these patients.1 In a similar multikinase inhibitor strategy, lenvatinib was found to be noninferior to sorafenib in overall survival in the same patient...
AACR Recognizes Achievements of Three Cancer Researchers
The American Association for Cancer Research (AACR) is honoring three clinical cancer researchers for their outstanding achievements. Jedd D. Wolchok, MD, PhD, FASCO, will receive the 2020 AACR–Joseph H. Burchenal Award for Outstanding Achievement in Clinical Cancer Research. Lisa A. Newman, MD,...
Two Studies Validate Neoadjuvant Chemotherapy With Short-Course Radiotherapy or Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer
In the treatment of resectable, locally advanced rectal cancer, researchers are trying to identify the most effective chemotherapy regimens, the best radiotherapy approaches, and the optimal sequence of these modalities. Two phase III trials presented during the ASCO20 Virtual Scientific Program...
Adjuvant Atezolizumab Fails to Meet Primary Study Endpoint in High-Risk Bladder Cancer
Adjuvant atezolizumab, a PD-L1–blocking antibody, failed to meet the primary endpoint of disease-free survival in patients at high risk of recurrence of muscle-invasive bladder cancer compared with observation alone, according to the primary analysis of the IMvigor010 trial reported during the...
Expert Point of View: Suzanne Lentzsch, MD, PhD, and Joshua Richter, MD
Two myeloma specialists weighed in on the disappointing findings of SWOG S1211: Suzanne Lentzsch, MD, PhD, Professor of Medicine at Columbia University and Director of the Multiple Myeloma and Amyloidosis Service, and Joshua Richter, MD, Assistant Professor of Medicine, Icahn School of Medicine at...
Roundup of High-Impact Studies in Early Breast Cancer
Clinicians interested in breast cancer who logged into the ASCO20 Virtual Scientific Program were greeted with an abundance of high-impact presentations. The ASCO Post has reported on several studies in depth elsewhere, but here we offer our readers a roundup of several important studies in early...
IMbrave150 Trial: Atezolizumab Plus Bevacizumab Improves Survival in Unresectable Hepatocellular Carcinoma
As reported in The New England Journal of Medicine by Richard S. Finn, MD, of Jonsson Comprehensive Cancer Center, Geffen School of Medicine at the University of California, Los Angeles, and colleagues, the phase III IMbrave150 trial has shown that anti–programmed cell death ligand 1 (PD-L1) plus...
Geriatric Assessment: What Are You Waiting For?
The ASCO20 Virtual Scientific Program was the forum for an unusual but profoundly important event in oncology. Four studies that should be practice-changing were presented.1-4 These studies provided irrefutable evidence that we can improve the quality of life of older patients by reducing toxicity. ...
Responses Achieved With Belantamab Mafodotin in Relapsed or Refractory Myeloma
The antibody-drug conjugate belantamab mafodotin yielded responses as a single agent and in combination with bortezomib and dexamethasone in the treatment of relapsed or refractory multiple myeloma, according to two reports from the DREAMM team at the ASCO20 Virtual Scientific Program.1,2 In the...
Phase II Study Evaluates Chemotherapy and Immunotherapy in Patients With Malignant Pleural Mesothelioma
Data from the phase II PrE0505 multicenter trial showed that adding durvalumab, an immune checkpoint antibody targeting programmed cell death ligand 1 (PD-L1), to the combination of cisplatin and pemetrexed chemotherapy improved outcomes in previously untreated patients with unresectable malignant...
Nivolumab Plus Ipilimumab in Two New Lung Cancer Indications
The combination of nivolumab and ipilimumab was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with non–small cell lung cancer (NSCLC) in two different regimens: On May 15, 2020, the two-drug combination was approved for first-line treatment in...
Daratumumab and Hyaluronidase-fihj for Multiple Myeloma
On May 1, 2020, the combination of daratumumab and hyaluronidase-fihj was approved for adult patients with newly diagnosed or relapsed/refractory multiple myeloma. This new product allows for subcutaneous (SC) dosing of daratumumab.1,2 Daratumumab and hyaluronidase-fihj is for SC use only. The...
